TABLE 1.
Comparison of non-susceptibility rates between clinical and screening ESBL-producing E. coli and K. pneumoniae.
|
E. coli |
K. pneumonia |
|||||
|
% Non-susceptible (no. isolates tested) |
% Non-susceptible (no. isolates tested) |
|||||
| Clinical | Screening | p | Clinical | Screening | p | |
| CRO | 100 (52) | 99 (202) | 0.4 | 100 (17) | 98.2 (56) | 0.6 |
| CAZ | 63.5 (52) | 58.9 (202) | 0.5 | 100 (17) | 83.9 (56) | 0.07 |
| FEP | 92.3 (52) | 62.4 (202) | < 0.001 | 100 (17) | 66.1 (56) | < 0.01 |
| AZT | 83.7 (49) | 84.4 (122) | 0.9 | 100 (17) | 89.7 (29) | 0.2 |
| AMC | 36.5 (52) | 48.5 (202) | 0.1 | 58.8 (17) | 76.8 (56) | 0.1 |
| TZP | 15.4 (52) | 11.9 (202) | 0.4 | 35.3 (17) | 28.6 (56) | 0.6 |
| ERT | 1.9 (1/52) | 5.9 (202) | 0.2 | 5.9 (17) | 10.7 (56) | 0.6 |
| MEM | 0 (52) | 3.9 (202) | 0.1 | 5.9 (17) | 8.9 (56) | 0.7 |
| GEN | 25 (52) | 16.3 (202) | 0.1 | 35.3 (17) | 28.6 (56) | 0.6 |
| AMK | 1.9 (52) | 0.5 (202) | 0.3 | 0 (17) | 5.4 (56) | 0.3 |
| CIP | 48.1 (52) | 39.6 (202) | 0.3 | 47.1 (17) | 39.3 (56) | 0.6 |
| LVX | 44.2 (52) | 41.8 (184) | 0.8 | 11.8 (17) | 20 (50) | 0.4 |
| SXT | 61.5 (52) | 66.8 (202) | 0.4 | 88.2 (17) | 73.2 (56) | 0.2 |
| NIT | 0 (52) | 9.9 (202) | 0.02 | 41.2 (17) | 64.3 (56) | 0.09 |
CRO, ceftriaxone; CAZ, ceftazidime; FEP, cefepime; AZT, aztreonam; AMC, amoxicillin-clavulanate; AMS, TZP, piperacillin-tazobactam; ERT, ertapenem; MEM, meropenem; GEN, gentamicin; AMK, amikacin; CIP, ciprofloxacin; LVX, levofloxacin; SXT, trimethoprim-sulfametoxazole; NIT, nitrofurantoin.